Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News

TOP industry news from Business Wire

Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical CongressOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company’s drug discovery research in immuno-oncology will be highlighted in an oral presentation at the American College of Surgeons (ACS) 2017 Clinical Congress taking place October 22-26 in San Diego. The research is part of a collaboration with the Lowy laboratory


Company Profile for M3 Biotechnology, Inc.Open in a New Window

--(BUSINESS WIRE)--M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.   Company: M3 Biotechnology, Inc.   Headquarters Address


RenovaCare Announces Successful Closing of FinancingOpen in a New Window

NEW YORK & PITTSBURGH & BERLIN--(BUSINESS WIRE)--RenovaCare, Inc., (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants”) to purchase 915,000


Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual MeetingOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT) announced that data presented at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada demonstrate the accuracy of identification of BRAF V600E and parathyroid tissue through new classifiers developed in conjunction with the next-generation Afirma Genomic Sequencing Classifier. The BRAF V600E and parathyroid classifiers were designed to further reduce unnecess


Global $6.4 Billion Molecular Spectroscopy Market to 2024 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Molecular Spectroscopy Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024" report has been added to Research and Markets' offering. Global molecular spectroscopy market is projected to reach USD 6,443.5 million by 2024, from USD 3,959.8 million in 2016, growing at a CAGR of 6.3% in the forecast period. The global molecular spectroscopy market is segmented on the basis of technology, type, application, and geography. Based o


Spineology Initiates Post-Market Lateral Interbody Fusion Study Using Novel Implant DesignOpen in a New Window

ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology initiating prospective, post-market lateral interbody fusion study designed to evaluate patient outcomes using its FDA-cleared Duo.


PharmaCyte Biotech to Hold Shareholder CallOpen in a New Window

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--#INDstatus--PharmaCyte CEO to conduct a shareholder call to update shareholders on IND, trial preparations and diabetes program.


ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial ResultsOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business. To access the live call by phone, dial 719-325-4907; the conference ID is 6498153. The call also may be accessed throug


Biden Cancer Initiative President & FasterCures Executive Director to Keynote Georgia Bio Innovation Summit October 24Open in a New Window

ATLANTA--(BUSINESS WIRE)--The Georgia Bio Innovation Summit on October 24 will welcome Greg Simon, of the Biden Cancer Initiative, and Kim McCleary of FasterCures as keynotes.


Resumen: Pharnext: resultados financieros primer semestre de 2017Open in a New Window

PARÍS--(BUSINESS WIRE)--Pharnext SA (FR00111911287 - ALPHA), una compañía biofarmacéutica pionera en un nuevo enfoque para el desarrollo de fármacos innovadores basados en la combinación y reposicionamiento de medicamentos conocidos, ha anunciado los resultados correspondientes al primer semestre de 2017. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es l


Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®Open in a New Window

WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from


Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017Open in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced new data presentations on EDP-305, Enanta’s lead Farnesoid X receptor (FXR) agonist being developed for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), will be presented at The Liver Meeting® 2017, the Annual Meeting of the American Ass


Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye SyndromeOpen in a New Window

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement of these new indications, in a


Agilis Biotherapeutics Announces Presentations on Angelman Syndrome Program at ESGCT and NORD Rare Disease SummitOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#Agilis--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today two presentations on its gene therapy program for Angelman syndrome (AS). A poster presentation entitled, “The A-BOM: Collaborating to identify patient-centered biomarkers and outcome measures for Angelman Syndrome” was presented on October 16, 2017, at the National Organiza


Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering DiscussionsOpen in a New Window



The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 25Open in a New Window

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its third-quarter 2017 financial results and operational developments. A live audio webcast of the conference call may be accessed in the Investors section of The Medicines Company website. A replay of the webcast will be available on the website following the conference call. The conference call may also be accessed by telepho


Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017Open in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #AASLD--Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017


Global Circulating Tumor Cell (CTC) Diagnostics Market 2017-2021 - Key Vendos are ApoCell, Qiagen & Menarini Silicon Biosystems - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Circulating Tumor Cell (CTC) Diagnostics Market 2017-2021" report has been added to Research and Markets' offering. The global circulating tumor cell (CTC) diagnostics market to grow at a CAGR of 9.39% during the period 2017-2021. The report covers the present scenario and the growth prospects of the global circulating tumor cell (CTC) diagnostics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way


Samenvatting: AMRA en BioTelemetry Research leggen lat hoger bij beeldtechniek voor klinisch onderzoek naar NASH/NAFLDOpen in a New Window

LINKÖPING, Sweden & MALVERN, Pa.--(BUSINESS WIRE)--AMRA, internationaal leider in analyses van de lichaamssamenstelling, en BioTelemetry Research (BTR), een wereldwijd toonaangevend laboratorium in cardiologie en weergave, hebben vandaag aangekondigd een exclusieve alliantie aan te gaan voor klinisch-wetenschappelijk onderzoek op vlak van niet-alcoholische leververvetting en niet-alcoholische steatohepatitis. Deze unieke samenwerking helpt medische weergavetechniek vooruit en komt zodoende spon


Resumen: AMRA y BioTelemetry Research impulsan los límites de la imagen médica en los ensayos clínicos de EHNA/ EHGNAOpen in a New Window

LINKÖPING, Suecia & MALVERN, Pensilvania--(BUSINESS WIRE)--AMRA, líder internacional en análisis de composición corporal, y BioTelemetry Research ("BTR"), un laboratorio central líder especializado en imágenes y análisis cardiacos, han anunciado la formación de una alianza exclusiva para ensayos clínicos que relacionados con la enfermedad del hígado graso no alcohólico (EHGNA) y la esteatohepatitis no alcohólica (EHNA). La primera alianza de este tipo en el mercado permitirá avanzar la ciencia


Global Antibody Drugs Technologies and Markets, 2022 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Antibody Drugs: Technologies and Global Markets" report has been added to Research and Markets' offering. The Global Market for Antibody Drugs Should Reach $114.6 Billion by 2022 Increasing from $84.5 Billion in 2017, at a CAGR of 6.3% from 2017 Through 2022 Report Includes An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies. Analyses of global market trends, with data from 2014, 2015 and 2016,


Institut Curie and Pierre Fabre Initiate a Novel Partnership in Immuno-OncologyOpen in a New Window

PARIS & CASTRES, France--(BUSINESS WIRE)--Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models. “We will work to better understand the immunological responses to tumors, and


L’institut Curie et Pierre Fabre mettent en place un partenariat novateur en immuno-oncologieOpen in a New Window

PARIS & CASTRES, France--(BUSINESS WIRE)--L’Institut Curie et l’IRPF (Institut de Recherche Pierre Fabre) collaboreront sur de nouvelles stratégies thérapeutiques pour faire progresser le traitement du cancer chez les patients. L’objectif de ce nouveau partenariat est d’analyser la biologie de nouvelles cibles thérapeutiques identifiables et d’évaluer l’impact des approches pharmacologiques innovantes en s’appuyant sur des modèles biologiques de l’Institut Curie. « Nous allons travailler pour m


Abionic Announces FDA Registration for World’s Most Rapid Allergy Test and abioSCOPE® Diagnostic Testing PlatformOpen in a New Window

LAUSANNE, Switzerland--(BUSINESS WIRE)--Abionic's rapid allergy test, IVD CAPSULE Aeroallergens, and the testing platform, abioSCOPE, have been registered in the US by the FDA.


Characterizing Bacteriophage-Derived Enzymes That Degrade Staphylococcus BiofilmsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Biofilms are surface-attached communities of bacterial or fungal cells that are enmeshed in an extensive extracellular matrix which makes them more resistant to both antibiotics and the immune system. With biofilms estimated to be responsible for >60% of microbial infections, and 80% of chronic infections in humans, finding ways to disrupt established biofilms is of critical importance. In recent years there has been a growing interest in exploiting bacteriophages


Growth Energy, BIO to EPA: Proposed Biodiesel Reductions Would Roll Back the RFSOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--#RFS--Growth Energy and BIO submit joint comments on EPA's proposal to reduce biodiesel, advanced and overall RFS volumes in 2018.


Pharnext: Erstes Halbjahr 2017Open in a New Window

PARIS--(BUSINESS WIRE)--Pharnext SA (FR00111911287 - ALPHA), ein biopharmazeutisches Unternehmen mit einem neuartigen Ansatz für die Entwicklung innovativer Arzneimittel, der auf der Kombination und Neupositionierung von bekannten Arzneimitteln beruht, legte heute seine Finanzergebnisse für das erste Halbjahr 2017 vor. Prof. Dr. med. Daniel Cohen, Mitbegründer und CEO, äußerte sich zur Geschäftstätigkeit im ersten Halbjahr 2017 wie folgt: „Im ersten Halbjahr ist sehr viel passiert. Wir haben zw


AMRA und BioTelemetry Research erhöhen den Standard für medizinische Bildgebung im Rahmen klinischer NASH/NAFLD-StudienOpen in a New Window

LINKÖPING (Schweden) und MALVERN (USA, Pennsylvania)--(BUSINESS WIRE)--AMRA and BioTelemetry Research announce exclusive alliance for clinical trials in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.


Ignyta Announces Pricing of Public Offering of Common StockOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share. The gross proceeds from this offering are expected to be $160.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to
Association Management Software Powered by YourMembership  ::  Legal